Oral treatment to slow endometriosis and reduce pain
Official title: Phase II- Repurposing CRH antagonists for the treatment of endometriosis
Funded at Sur180 Therapeutics, LLC · NIH-11331307 · Data updated 2026-11-12
This project tests an oral drug to slow endometriosis progression and ease pain, with the goal of reducing the need for repeated surgeries.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sur180 Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Mcallen, United States) |
| Project start | June 1, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,140,501 |
| NIH project number | 5R44HD109055-03 |
| Project ID | NIH-11331307 on NIH RePORTER |
Who could benefit from this research
✓Could help
Women and teenagers diagnosed with endometriosis who are seeking non-surgical management options and long-term pain relief.
✕Less likely to help
Patients seeking immediate surgical cure or those with conditions that contraindicate oral therapy may not benefit.
What this research studies
Endometriosis is a chronic condition causing pain and infertility for many women. The project aims to advance an oral therapy that can slow disease progression and relieve pain, potentially decreasing the number of surgeries patients need. Phase II SBIR work will de-risk the therapy and move it toward broader use, building on promising animal data that showed pain reduction and lasting effects after treatment. If successful, the drug could offer a long-term, non-surgical option for managing endometriosis. The work is conducted by Sur180 Therapeutics, LLC, with a focus on translating preclinical findings into a treatment that patients could take to manage their condition.
Why it matters
Potential benefit: If successful, patients with endometriosis could experience reduced pain and slower disease progression, with fewer surgeries needed.
How similar studies have gone: Previous preclinical data in animal models showed reduced pain and markers of proliferation with the drug candidate, supporting potential benefit in humans.
Where this research is happening
-
Sur180 Therapeutics, LLC
Mcallen, United States Active
Researchers
- Principal investigator: Torres-Reveron, Annelyn — Sur180 Therapeutics, LLC
- Study coordinator: Torres-Reveron, Annelyn
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to endometriosis-related infertility
This grant explores how molecular changes in endometriosis contribute to infertility, with the aim of finding better ways to diagnose and treat the condition.
-
Hormonal Influences on Inflammation in Endometriosis
A study in adult women with endometriosis looks at how hormones and immune pathways interact to influence inflammation and symptoms.
-
How genes influence endometriosis in women of different racial and ethnic backgrounds
The team will compare genetic changes in tissue from women of various races who have endometriosis to find molecular targets for better treatments.
-
Quantum diamond sensor endoscopy to map iron in endometriosis
A tiny quantum sensor built into an endoscope will map iron in endometriosis lesions to help diagnose the disease noninvasively.
-
Understanding how RPLP1 affects endometriosis and adenomyosis
A patient-focused look at how a ribosomal protein called RPLP1 may drive tissue changes in endometriosis and adenomyosis and what this could mean for future therapies.
-
CXCR4 methylation in endometriosis and its role as an early biomarker and non-hormonal therapy target
This project explores how changes in CXCR4 gene regulation may help diagnose endometriosis earlier and point toward non-hormonal treatments for the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.